蛋白芯片法检测弥漫大B细胞淋巴瘤患者血清β2微球蛋白和血管内皮生长因子蛋白表达的临床意义

摘要

Objective To investigate the expression and clinical significance of β2 microglobin (β2-MG)protien and vascular endothelial growth factor (VEGF) protien in diffuse large B-cell lymphoma (DLBCL).Methods The expressions of VEGF protien and β2-MG protien were evaluated in 49 DLBCL patients which started the initial treatment by luminex suspension array.Results Among 49 DLBCL patients,expression of β2-MG protein was high in 37 cases and the expression of VEGF protein was high in 23 cases.The expression of VEGF protien and β2-MG protien were not related with gender,age,B symptoms,clinical stage and lactic acid (LDH).There was positive correlation between the high expression of β2-MG protien and chemotherapy (P =0.037).There was relevant trend between the higher expression of VEGF protien (P =0.067).Conclusion The expressions of VEGF protien and β2-MG protien are detected in DLBCL,both proteins may be the potencial markers of DLBCL and therapeutic targets for DLBCL.%目的 探讨β2微球蛋白(β2-MG)和血管内皮生长因子(VEGF)在弥漫大B细胞淋巴瘤(DLBCL)中的表达及意义.方法 Luminex液相芯片法检测初治49例DLBCL患者治疗前血清VEGF 和β2-MG蛋白表达水平的变化,分析二者与临床病理因素的关系.结果 49例DLBCL患者中,β2-MG 高表达37例,VEGF高表达23例.β2-MG和VEGF蛋白高表达与患者的性别、年龄、有无B组症状、临床分期、乳酸脱氢酶(LDH)的增高均无相关性(均P＞ 0.05).β2-MG高表达与以CHOP方案为基础的全身化疗效果相关(P=0.037).VEGF蛋白高表达与合并纵隔侵犯有相关趋势,但差异无统计学意义(P=0.067).结论 蛋白芯片法检测β2-MG和VEGF蛋白表达水平有望成为DLBCL常规临床诊断和治疗方案选择的新方法.